Anacetrapibisacholesterolestertransferprotein(CETP)inhibitorthatexhibitsanti-atheroscleroticactivity.Invivo,anacetrapibinhibitsthedevelopmentofatherosclerosisanddecreaseslevelsofVLDLandPCSK9.Inaclinicalsetting,thiscompounddecreaseslevelsofLDLandApoB.Additionally,anacetrapibmayincreaselevelsofHDLandApoA1.
| Purity | ≥98% |
|---|---|
| Formula | C30H25F10NO3 |
| FormulaWt. | 637.52 |
| Synonym | MK-0859 |
| Appearance | Whitepowder |
| StoreTemp | -20°C |
|---|
| InfoSheet | A5301InfoSheetPDF |
|---|
vanderTuinSJ,KühnastS,BerbéeJF,etal.Anacetrapibreduces(V)LDLcholesterolbyinhibitionofCETPactivityandreductionofplasmaPCSK9.JLipidRes.2015Nov;56(11):2085-93.PMID:26342106.
MillarJS,Reyes-SofferG,JumesP,etal.AnacetrapiblowersLDLbyincreasingApoBclearanceinmildlyhypercholesterolemicsubjects.JClinInvest.2015Jun;125(6):2510-22.PMID:25961461.
ÄijänenT,KoivuniemiA,JavanainenM,etal.Howanacetrapibinhibitstheactivityofthecholesterylestertransferprotein?Perspectivethroughatomisticsimulations.PLoSComputBiol.2014Nov20;10(11):e1003987.PMID:25412509.
HooperAJ,BurnettJR.Anacetrapib,acholesterylestertransferproteininhibitor.ExpertOpinInvestigDrugs.2012Jan;21(1):103-9.PMID:22191425.
